Results 51 to 54 of about 9,492 (54)
Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis. [PDF]
Majda T, Lee JS, Curtis R, Kowal SL.
europepmc +1 more source
Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis. [PDF]